the cooper cos. inc. - COO
COO
Close Chg Chg %
75.98 1.05 1.38%
Closed Market
77.03
+1.05 (1.38%)
Volume: 5.13M
Last Updated:
Dec 4, 2025, 4:00 PM EDT
Company Overview: the cooper cos. inc. - COO
COO Key Data
| Open $76.05 | Day Range 75.92 - 77.58 |
| 52 Week Range 61.78 - 104.47 | Market Cap $15.11B |
| Shares Outstanding 198.81M | Public Float 197.52M |
| Beta 1.05 | Rev. Per Employee N/A |
| P/E Ratio 37.34 | EPS $2.04 |
| Yield 0.00% | Dividend $0.03 |
| EX-DIVIDEND DATE Jul 26, 2023 | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.87M |
COO Performance
| 1 Week | -1.15% | ||
| 1 Month | 9.89% | ||
| 3 Months | 13.13% | ||
| 1 Year | -21.96% | ||
| 5 Years | -10.87% |
COO Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
21
Full Ratings ➔
About the cooper cos. inc. - COO
The Cooper Cos, Inc. operates as a medical device company. It operates through the Cooper Vision and Cooper Surgical segments. The Cooper Vision segment develops, manufactures, and markets products for contact lens wearers, which solves vision challenges such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues. The Cooper Surgical segment focuses on the provision of advancement for the health of women, babies, and families through women's health and fertility products and services. The company was founded in 1958 and is headquartered in San Ramon, CA.
COO At a Glance
The Cooper Cos., Inc.
6101 Bollinger Canyon Road
San Ramon, California 94583
| Phone | 1-925-460-3600 | Revenue | 3.90B | |
| Industry | Medical Specialties | Net Income | 392.30M | |
| Sector | Health Technology | 2024 Sales Growth | 8.41% | |
| Fiscal Year-end | 10 / 2025 | Employees | 16,000 | |
| View SEC Filings |
COO Valuation
| P/E Current | 37.339 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 53.474 |
| Price to Sales Ratio | 5.385 |
| Price to Book Ratio | 2.585 |
| Price to Cash Flow Ratio | 29.58 |
| Enterprise Value to EBITDA | 21.191 |
| Enterprise Value to Sales | 6.09 |
| Total Debt to Enterprise Value | 0.12 |
COO Efficiency
| Revenue/Employee | 243,462.50 |
| Income Per Employee | 24,518.75 |
| Receivables Turnover | 5.433 |
| Total Asset Turnover | 0.325 |
COO Liquidity
| Current Ratio | 1.908 |
| Quick Ratio | 1.123 |
| Cash Ratio | 0.105 |
COO Profitability
| Gross Margin | 61.47 |
| Operating Margin | 18.116 |
| Pretax Margin | 14.948 |
| Net Margin | 10.071 |
| Return on Assets | 3.273 |
| Return on Equity | 5.018 |
| Return on Total Capital | 3.587 |
| Return on Invested Capital | 3.709 |
COO Capital Structure
| Total Debt to Total Equity | 35.296 |
| Total Debt to Total Capital | 26.088 |
| Total Debt to Total Assets | 23.167 |
| Long-Term Debt to Equity | 34.406 |
| Long-Term Debt to Total Capital | 25.43 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for The Cooper Cos. Inc. - COO
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 2.92B | 3.31B | 3.59B | 3.90B | |
Sales Growth
| +20.22% | +13.20% | +8.61% | +8.41% | |
Cost of Goods Sold (COGS) incl D&A
| 1.11B | 1.32B | 1.42B | 1.50B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 341.10M | 378.30M | 407.70M | 413.80M | |
Depreciation
| 195.00M | 198.80M | 221.50M | 212.60M | |
Amortization of Intangibles
| 146.10M | 179.50M | 186.20M | 201.20M | |
COGS Growth
| +8.38% | +18.76% | +7.56% | +5.59% | |
Gross Income
| 1.81B | 1.99B | 2.17B | 2.39B | |
Gross Income Growth
| +28.89% | +9.79% | +9.31% | +10.26% | |
Gross Profit Margin
| +61.92% | +60.05% | +60.44% | +61.47% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.28B | 1.44B | 1.67B | 1.69B | |
Research & Development
| 92.70M | 110.30M | 137.40M | 155.10M | |
Other SG&A
| 1.19B | 1.33B | 1.53B | 1.53B | |
SGA Growth
| +20.51% | +11.76% | +16.35% | +1.10% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 7.70M | (4.20M) | (31.80M) | |
EBIT after Unusual Expense
| 517.40M | 555.30M | 533.10M | 705.70M | |
Non Operating Income/Expense
| 5.20M | (25.00M) | (58.00M) | (64.10M) | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 31.10M | 55.00M | 62.20M | 59.30M | |
Interest Expense Growth
| -15.49% | +76.85% | +13.09% | -4.66% | |
Gross Interest Expense
| 38.90M | 55.00M | 62.20M | 59.30M | |
Interest Capitalized
| - | - | - | 7.80M | - |
Pretax Income
| 491.50M | 475.30M | 412.90M | 582.30M | |
Pretax Income Growth
| +84.43% | -3.30% | -13.13% | +41.03% | |
Pretax Margin
| +16.82% | +14.37% | +11.49% | +14.95% | |
Income Tax
| (2.45B) | 89.50M | 118.70M | 190.00M | |
Income Tax - Current - Domestic
| 22.30M | 14.00M | 41.00M | 39.50M | |
Income Tax - Current - Foreign
| 26.70M | 21.70M | 33.00M | 31.60M | |
Income Tax - Deferred - Domestic
| (9.30M) | 8.20M | (44.20M) | (19.10M) | |
Income Tax - Deferred - Foreign
| (2.49B) | 45.60M | 88.90M | 138.00M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 2.94B | 385.80M | 294.20M | 392.30M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 2.94B | 385.80M | 294.20M | 392.30M | |
Net Income Growth
| +1,135.19% | -86.90% | -23.74% | +33.34% | |
Net Margin Growth
| +100.76% | +11.66% | +8.19% | +10.07% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 2.94B | 385.80M | 294.20M | 392.30M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 2.94B | 385.80M | 294.20M | 392.30M | |
EPS (Basic)
| 14.9629 | 1.9564 | 1.4859 | 1.9724 | |
EPS (Basic) Growth
| +1,132.63% | -86.92% | -24.05% | +32.74% | |
Basic Shares Outstanding
| 196.80M | 197.20M | 198.00M | 198.90M | |
EPS (Diluted)
| 14.7826 | 1.9406 | 1.4769 | 1.9576 | |
EPS (Diluted) Growth
| +1,130.24% | -86.87% | -23.89% | +32.55% | |
Diluted Shares Outstanding
| 199.20M | 198.80M | 199.20M | 200.40M | |
EBITDA
| 866.20M | 929.40M | 909.00M | 1.12B | |
EBITDA Growth
| +31.70% | +7.30% | -2.19% | +23.16% | |
EBITDA Margin
| +29.64% | +28.09% | +25.30% | +28.74% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 81.875 | |
| Number of Ratings | 21 | Current Quarters Estimate | 1.004 | |
| FY Report Date | 01 / 2026 | Current Year's Estimate | 4.416 | |
| Last Quarter’s Earnings | 1.15 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 4.12 | Next Fiscal Year Estimate | 4.832 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 13 | 13 | 18 | 16 |
| Mean Estimate | 1.00 | 1.05 | 4.42 | 4.83 |
| High Estimates | 1.03 | 1.09 | 4.52 | 4.97 |
| Low Estimate | 0.97 | 1.01 | 4.31 | 4.62 |
| Coefficient of Variance | 1.97 | 2.47 | 1.52 | 2.43 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 10 |
| OVERWEIGHT | 5 | 5 | 3 |
| HOLD | 7 | 7 | 6 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for The Cooper Cos. Inc. - COO
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for The Cooper Cos. Inc. - COO
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 4, 2025 | Cynthia L. Lucchese Director | 3,322 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Maria Rivas Director | 3,322 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Agostino Ricupati SVP & CAO | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Agostino Ricupati SVP & CAO | 8,020 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $81.27 per share | 651,785.40 |
| Apr 4, 2025 | Agostino Ricupati SVP & CAO | 9,044 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Robert S. Weiss Director | 3,654 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Robert S. Weiss Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Robert S. Weiss Director | 288,945 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Colleen E. Jay Director | 3,322 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Colleen E. Jay Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Colleen E. Jay Director | 29,521 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Teresa S. Madden Director | 12,357 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Cynthia L. Lucchese Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Cynthia L. Lucchese Director | 7,661 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | William A. Kozy Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | William A. Kozy Director | 31,149 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Lawrence Erik Kurzius Director | 3,322 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 4, 2025 | Lawrence Erik Kurzius Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Lawrence Erik Kurzius Director | 3,777 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Teresa S. Madden Director | 3,322 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |